Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)
← catalyst calendarNCT06744335 · readout in 1 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,283actual
Sites
28
Country
Kazakhstan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | 2026-08-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-20 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rate of CKD Diagnosis in Patients With AH and CKD Markers
- Demographic and Clinical Characteristics for Those Patients
- Routine Therapy Before and After the Diagnosis of CKD
Primary outcome
what the primary-completion date above is the date OFThe proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
measured 16 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed